Alex Chehrazi-Raffle, MD
@arafflemd
Followers
608
Following
691
Statuses
306
I am a GU medical oncologist at City of Hope Comprehensive Cancer Center, music enthusiast, and proud dog father. Tweets are my own.
Duarte, CA
Joined February 2020
RT @montypal: We are getting awfully close to a full house for #SoCalGU25! Come join us at the @BalboaBayClub on Friday, Feb 28, for full d…
0
12
0
RT @EbrahimiHedyeh: Southern California fellows, residents, medical students, and early-career researchers in #GU cancers: Showcase your l…
0
4
0
@ConquerCancerFd @ASCO Congrats to all of the @ConquerCancerFd merit award recipients, especially our very own @EbrahimiHedyeh! @CityofHope_GU @COHMedOnc @AbhiTrip87 @charlesbnguyen @TDorffOnc @montypal
0
4
15
RT @montypal: A meeting for my #SoCal colleagues. No lengthy travel required. Join us in #NewportBeach to discuss the current status of cli…
0
13
0
RT @neerajaiims: Congrats to 3 young investigators👇from @Huntsman_GU for @ASCO #GU25 @ConquerCancerFd Merit Award! @ziremozay @nsayeghmd #D…
0
21
0
RT @montypal: We are so honored to have esteemed international guests like @AndreaNecchi @MichvdHeijden @tompowles1 @AlbigesL @crisuarez08…
0
9
0
RT @crisbergerot: Mindfulness via smartphone @AmDTx_official Mentored by @montypal & @Linda_E_Carlson, this multinational study demonstrat…
0
29
0
RT @EAntonarakis: The two faces of FOXA1 muts in PCa. Congrats to Justin Hwang for this revised classification of FOXA1 alts in PCa. Differ…
0
16
0
RT @DrChoueiri: 1/ Results from #LITESPARK-003 cohort 1 (1st Line) are out @TheLancetOncol! This phase II trial examined HIF2 inh Belzutifa…
0
40
0
RT @ReginaBarCar: 🚨 New Paper Alert! 🚨 Excited to share our latest review on 1st and 2nd -line treatments in mRCC in @EUplatinum , co-autho…
0
55
0
🔈We Are Hiring!🔈 My lab at @CityofHope_GU has a post-doc position opening up in 2025. Candidates must have prior research experience, completed their MD/DO, and a passion for clinical & translational GU oncology research. DM me if interested!
6
16
43
RT @urotoday: Advancing treatment for high-risk biochemical recurrence #ProstateCancer. @arafflemd @cityofhop sits with @zklaassen_md @GACa…
0
9
0
RT @DrChoueiri: 1/ Results from #TiNivo2 are out both @myEsmo #ESMO24 and @TheLancet! Another phase 3 trial to assess the efficacy of immun…
0
50
0
RT @montypal: So proud of @ReginaBarCar @mzugman & @EbrahimiHedyeh - my current @cityofhope fellows - who knocked it out of the park at the…
0
16
0
RT @EbrahimiHedyeh: Day 3 of #ESMO24 and a stellar presentation by @ciccarese_c on the preliminary results of the TACITO trial, exploring f…
0
10
0
RT @montypal: Awesome presentation from @DrChoueiri at #ESMO24. Huge congrats on the accompanying paper in @TheLancet - super proud of my @…
0
18
0
Hot off the presses: TiNivo-2 shows no benefit from PD-1 re-challenge in #mRCC but does underscore efficacy of #tivozanib as 2L therapy with minimal tox. Many thx to @DrChoueiri @montypal for the opportunity to contribute to this practice-informing study!
0
2
20
@urotoday @zklaassen_md @GACancerCenter Many thanks for the invitation @urotoday @zklaassen_md @BayerPharma! Hopefully #ARASTEP will clarify whether pts w/PSMA PET/CT(+) conventional imaging(-) biochemical recurrence will benefit from 2y ADT+darolutamide vs 2y ADT alone. @CaPsurvivorship @EAntonarakis
0
0
5
RT @oncodaily: Two recent papers studying BRAF alterations in PCa @EAntonarakis, @eamontoye13, @arafflemd
#Resear…
0
2
0